Pharmacological impact on loop gain properties to prevent irregular breathing
H Kiwull-Schöne1, L Teppema, M Wiemann
1Department of Physiology, Ruhr-University Bochum, Germany. Heidrun.Kiwull-Schoene@rub.de
Summary
Carbonic anhydrase inhibitors and sodium/proton exchanger type 3 (NHE3) inhibitors effectively reduce respiratory loop gain (G) in anesthetized rabbits. This suggests potential therapeutic applications for irregular breathing disorders like sleep apnea.
Area of Science:
- Physiology
- Pharmacology
- Respiratory Medicine
Background:
- Respiratory instabilities are linked to elevated system loop gain (G).
- Factors influencing G include ventilatory CO2 sensitivity, set-point PCO2, and metabolic rate.
- Carbonic anhydrase (CA) and sodium/proton exchanger type 3 (NHE3) are implicated in respiratory control.
Purpose of the Study:
- To investigate the effects of CA and NHE3 inhibitors on system loop gain (G) in anesthetized rabbits.
- To explore the potential therapeutic implications of these inhibitors for irregular breathing disorders.
Main Methods:
- Administered CA inhibitors (acetazolamide, methazolamide) and NHE3 inhibitors to anesthetized rabbits.
- Measured changes in system loop gain (G) under varying arterial CO2 levels (PaCO2).
- Correlated findings with brainstem NHE3 mRNA expression.
Main Results:
- Acetazolamide and methazolamide significantly reduced G by 42.0% and 35.0%, respectively.
- NHE3 inhibition reduced G by 33.0% at elevated PaCO2 (35.5 mmHg), but not at lower levels.
- High baseline PCO2 correlated with elevated brainstem NHE3 mRNA expression.
Conclusions:
- Both CA and NHE3 inhibitors effectively reduce respiratory loop gain (G) in rabbits.
- NHE3 inhibitors show promise for treating irregular breathing, particularly at higher CO2 levels.
- Targeting NHE3 may offer a therapeutic strategy for conditions like sleep apnea and sudden infant death syndrome.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...